Form 4 Filing for Doyle Mittie at Avalo Therapeutics, Inc.

On May 15, 2026, Doyle Mittie, Chief Medical Officer at Avalo Therapeutics, Inc. (AVTX), executed a series of transactions involving the company's common stock. Mittie acquired 3,000 shares under a Rule 10b5-1 trading plan at a price of $12.65 per share, increasing their post-transaction holdings to 6,622 shares. Concurrently, Mittie disposed of 3,000 shares at $18.76 per share, resulting in 3,622 shares remaining. Additionally, Mittie exercised a stock option to acquire 3,000 shares, with the option vesting schedule noted as complex, and reported 128,625 shares following this transaction. The exercise price for the option was $12.65, and the option expires on July 15, 2034. These transactions were part of a pre-arranged trading plan.